Wedbush Reiterates TESARO Inc to Outperform with Price Target $164

Brokerage firm Wedbush Reiterates its rating on TESARO Inc(TSRO). As per the latest information, Wedbush Lowers the price target to $164 per share from a prior target of $200. The shares have been rated Outperform. The rating by the stock financial advisor at Wedbush was issued on Mar 15, 2017 in a research report to their Investors and Clients.

In a different note, On Feb 27, 2017, Baird said it Downgrades its rating on TESARO Inc. According to the research note, Baird Raises the price target to $182 per share from a prior target of $127. The shares have been rated ‘Neutral’ by the firm. On Feb 16, 2017, FBR Capital said it Downgrades its rating on TESARO Inc. According to the research note, FBR Capital Raises the price target to $202 per share from a prior target of $151. The shares have been rated ‘Market Perform’ by the firm. On Feb 10, 2017, Leerink Swann said it Downgrades its rating on TESARO Inc. The shares have been rated ‘Market Perform’ by the firm. Cowen & Co. said it Initiates Coverage On TESARO Inc, according to a research note issued on Feb 6, 2017. The shares have been rated ‘Market Perform’ by the firm.

TESARO Inc (TSRO) shares turned negative on Fridays trading session with the shares closing down -3.26 points or -2.13% at a volume of 16,31,804. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $153.12. The peak price level was also seen at $153.12 while the days lowest was $149.7. Finally the shares closed at $149.99. The 52-week high of the shares is $192.94 while the 52-week low is $36.68. According to the latest information available, the market cap of the company is $8,043 M.

TESARO Inc(TSRO) last announced its earnings results on Feb 28, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $4.225M. Analysts had an estimated revenue of $5.970M. Earnings per share were $-2.6. Analysts had estimated an EPS of $-1.95.

Several Insider Transactions has been reported to the SEC. On Mar 8, 2017, Edward C English (V.P. of Finance & Admin.) sold 10,000 shares at $178.06 per share price.Also, On Mar 3, 2017, Timothy R Pearson (Exec. VP, CFO) sold 1,447 shares at $177.61 per share price.On Mar 3, 2017, Orlando Oliveira (SVP & GM, International) sold 249 shares at $177.61 per share price, according to the Form-4 filing with the securities and exchange commission.

TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.

Add Comment